Incidence and predictors of sexually transmitted infections among adult HIV-positive patients receiving antiretroviral therapy at Themba Lethu HIV clinic in Johannesburg, South Africa

D Onoya,1 PhD; P Manjengwa,1 MPH; C Nattey,1 MSc; S Kgowedi,2 MSc; M Mbela,2 BSc; M Shumba,2 MB ChB; M P Fox3,4,5 DSc

1 Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2 Department of Global Health, Boston University School of Public Health, Boston, Mass, USA
3 Department of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 Department of Global Health, Boston University School of Public Health, Boston, Mass, USA
5 Department of Epidemiology, Boston University School of Public Health, Boston, Mass, USA

Corresponding author: D Onoya (donoya@heroza.org)

Background. Sexually transmitted infections (STIs) among people living with HIV/AIDS can facilitate the spread of HIV. Objectives. To estimate STI incidence and identify predictors of STI acquisition among HIV-positive patients during their first 24 months of antiretroviral therapy (ART) in Johannesburg, South Africa.

Methods. We conducted a cohort study using prospectively collected routine data on patients who initiated ART between January 2004 and January 2015 at the Themba Lethu HIV clinic in Johannesburg. Kaplan-Meier analysis was used to estimate STI incidence rates (based on evidence of laboratory diagnosis and STI syndromic treatment prescription records). STI predictors were identified using Cox regression analysis.

Results. Among 26 762 adult patients on ART, there were 1906 (7.1%) cases of STI (incidence 4.8/100 person-years; 95% confidence interval (CI) 4.7 - 5.1). Non-pregnant women were 60% more likely than men to be diagnosed with an STI (adjusted hazard ratio (aHR) 1.6; 95% CI 1.4 - 1.8). The risk of STI decreased with increasing baseline CD4 count (aHR 0.8, 0.5 and 0.4 for CD4 counts 101 - 200, 201 - 350 and >350 cells/µL, respectively, compared with CD4 count <100 cells/µL). Patients with advanced baseline World Health Organization (WHO) clinical stages had a higher risk (aHR 1.6 for WHO stage 4; 95% CI 1.3 - 1.9) compared with those with WHO stage 1. However, there was a 20% increase in the risk of STI among obese patients compared with underweight patients (aHR 1.3; 95% CI 1.0 - 1.7). Over 80% of obese patients diagnosed with an STI had a CD4 count <200 cells/µL.

Conclusions. STIs are common in HIV-infected patients who are receiving ART. While both ART and the syndromic management of STIs are high-impact interventions for controlling the spread of HIV, closer monitoring of STI occurrences is warranted, particularly among immunologically vulnerable patients.

S Afr Med J 2021;111(1):80-86. https://doi.org/10.7196/SAMJ.2021.v111i1.14672

Sexually transmitted infections (STIs) constitute important public health concerns in developing countries, where they account for 17% of illness-related economic losses.1 In South Africa (SA), a Spectrum model estimation exercise in 2017 reported Chlamydia trachomatis (CT) prevalence at 14.7% for men and 6.0% for women, Neisseria gonorrhoeae (NG) prevalence at 6.6% for men and 3.5% for women, and active syphilis prevalence at 0.5% for men and 0.97% for women.2 The 2015 SA antenatal care (ANC) survey reported syphilis prevalence of 2.0% among pregnant women attending public sector facilities, similar to levels observed in 2007 - 2008.3 In a 2013 study among adults in Johannesburg, 20.4% of all participants self-reported an STI episode (19.9% among HIV-infected participants).4

Untreated STIs can lead to long-term sequelae of infection. In adults, such manifestations occur in the reproductive system (genital ulceration, infertility, pelvic inflammatory disease), neurological system or cardiovascular system, and in infants, blindness or severe neurological disability is common.5,6 The prevention and early treatment of STIs are particularly crucial for SA because of the country’s high HIV burden. SA was estimated to have 7.9 million individuals living with HIV in 2017.7 Considering the high probability of HIV transmission when either sexual partner has an STI,[8,9] a high STI incidence among individuals living with HIV has considerable implications for containing the spread of HIV in general.

Several studies in developing countries have shown that treating STIs among HIV-infected patients significantly reduces the risk of transmission by reducing levels of HIV in genital secretions.[2,9] In 1995, SA adopted the syndromic approach to STI management, which entails the rapid treatment of STI cases identified by symptom screening rather than specific aetiology.10 Slight increases in STI prevalence were observed between 1990 and 2005 for NG...
(52.5% to 54.4% among women and 30.7% to 31.7% among men), while decreases were noted for trichomoniasis (30.9% to 24.2% among women and 5.9% to 4.0% among men), CT (11.5% to 10.1% among women and 8.7% to 7.1% among men) and syphilis (7.7% to 1.9% among women and 7.4% to 2.2% among men). Genital herpes simplex virus (HSV-2) prevalence appears to have increased slightly over time (52.5% to 54.4% among women and 30.7% to 31.7% among men). There is some evidence to suggest that genital ulcers are more likely to occur among HSV-2-infected individuals who are HIV-immunocompromised, and as the HIV epidemic matures, the contribution of HSV-2 to HIV transmission also increases. However, the proportion of new HIV infections in adults that were attributable to curable STIs also declined, from 39% in 1990 to 14% in 2010.

Despite its widespread benefits, syndromic STI management limits opportunities for diagnosis of asymptomatic infections and has been associated with poor reporting of STI cases. Many of the modelled STI prevalence estimates in SA rely heavily on data from ANC surveys, research studies and clinical trials. There is limited information on STI incidence rates across both HIV-infected and uninfected populations, and even fewer data for HIV-infected individuals who are receiving antiretroviral therapy (ART).

**Objectives**

To estimate the incidence of STIs among HIV-positive adults receiving care at the Themba Lethu HIV clinic in Johannesburg, SA.

**Methods**

**Study population**

We conducted a cohort study using prospectively collected data on adult HIV-positive (age ≥18 years) patients accessing standard first-line ART at the Themba Lethu HIV clinic in Johannesburg from January 2004 to January 2015. At the time of data collection, clinical data at Themba Lethu were routinely captured and stored in an electronic patient management system (TherapyEdge-HIV; Devex, USA). SA follows the syndromic approach for managing STIs, where patients are given a combination regimen based on the outcomes of a symptom screen during a medical visit. An STI symptom screen is recommended for all Themba Lethu ART patients every 3 months. Study participants were followed up via medical record review over 24 months after ART initiation to identify incident STIs. Incident STIs were determined from laboratory data, clinical notes and treatment prescription records, as defined in Table 1. As such, patients prescribed regimens consisting of recommended drugs for syndromic STI management on the clinic visits were also identified as incident STI cases in consultation with a prescribing clinician at the HIV clinic.

Demographic variables collected at the time of ART initiation (baseline) include age, gender, highest level of education (categorised as no education, primary school and secondary school), history of smoking (yes/no), history of alcohol use (yes/no) and employment status (employed/unemployed). Baseline clinical data include CD4 count, World Health Organization (WHO) clinical stage and body mass index (BMI). The primary outcome variable was the occurrence of an incident STI over 24 months after first-line ART initiation. Person-time accrued from the date of ART initiation to the first occurrence of an STI or the last time seen at the clinic (for patients who were lost to follow-up or transferred out, or died), or to the end of the observation period (24 months). Data were fully anonymised before statistical analysis. The study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (ref. no. M170564).

**Statistical analysis**

Continuous variables were described using medians and interquartile ranges (IQRs). Categorical variables were described using percentages. Kaplan-Meier analyses were conducted to determine STI incidence rates. Predictors of incident STIs among treated HIV-positive patients were modelled using Cox proportional hazards modelling. As our goal was to identify predictors and not assess causation, variables with a p-value < 0.1 in crude analyses were included in a multivariate model. Schoenfeld residuals were used to test the assumption of proportional hazards. Variables were excluded from the model when the inclusion of the interaction term did not resolve the proportional hazards assumption violation, in which case the model was stratified.

**Results**

**Cohort description and baseline characteristics**

Table 2 shows the distribution of baseline demographic and clinical characteristics of the 26 762 eligible patients. The overall median (IQR) age of the participants was 36.7 (31.0 - 43.4) years. Overall, 61.4% of participants were female. Female subjects were more likely than males to be ≤30 years old at ART initiation (29.2% v. 15.0%). Overall, 49.0% of the study participants were unemployed and 79.1% had a secondary-school level of education at ART initiation. Furthermore, a higher proportion of males than females reported a baseline history of alcohol consumption (24.8% v. 5.4%) or a history of smoking (18.6% v. 5.7%). Overall, 6.7% of the study sample had a history of tuberculosis at the time of ART initiation.

**STIs in HIV-positive adults on ART**

A total of 1 906 (7.1%) STI cases were identified. Of these, 708 were identified using clinical notes with prescribed medicines, and the remaining 1 198 were determined using the prescription information. Table 3 shows the proportions of STIs using the clinical notes with prescribed medication and prescription information (syndromic management). Of the 708 patients, 16.3% had anogenital warts, 13.7% had HSV-2 and only 2% had chancroid. The regimen-based STI cases were mostly prescribed metronidazole + ciprofloxacin (32.8%), metronidazole + ciprofloxacin + doxycycline (27.5%) or metronidazole + doxycycline (19.3%) (Table 4). The incidence of STIs was 4.9/100 person-years (py) (95% confidence interval (CI) 4.7 - 5.1). Among patients who had an incident STI on ART, 126 (6.6%) had two or more episodes during the period of observation. Only 213 (11.2%) of STI cases had HIV viral load data up to 6 months before or after the STI episode, and 74.2% of these were virally suppressed. The median (IQR) time to the first STI episode was 3.1 (0.7 - 9.9) months from the time of ART initiation.

Table 5 presents predictors of incident STIs among HIV-positive patients on ART. Women who were not pregnant at ART initiation were 60% more likely than men to have an incident STI (adjusted hazard ratio (aHR) 1.6; 95% CI 1.4 - 1.8) (Fig. 1). The risk of STI decreased with increasing age (aHR 0.6 for patients aged 41 - 50 years compared with ≤30 years; 95% CI 0.5 - 0.7). Patients with a low baseline CD4 count (<100 cells/µL) were at increased risk of incident STIs, with the risk decreasing with increasing baseline CD4 count (aHR 0.8, 0.5 and 0.4 for CD4 counts 101 - 200, 201 - 350 and >350 cells/µL, respectively, compared with CD4 count <100 cells/µL).
| Additional indications | Metronidazole | Ceftriaxone/ ciprofloxacin | Azithromycin/ doxycycline | Clotrimazole/ fluconazole | Benzathine penicillin | Acyclovir |
|------------------------|---------------|----------------------------|----------------------------|--------------------------|----------------------|-----------|
| Dosage                 | Oral, 2 g stat/400 mg 12-hourly for 7 days | IM, 250 mg stat | Oral, 1 g stat | Vaginal pessary 500 mg stat/cream 12-hourly for 7 days | IM, 2.4 MU stat/ doxycycline (oral, 100 mg 12-hourly for 14 days) if allergic to penicillin | Oral, 400 mg 8-hourly for 7 days |
| LAP                    | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| LAP, Lower abdominal tenderness and UTI and no indication for gynaecological/surgical assessment, if allergic to penicillin then omit ceftriaxone and increase azithromycin dose to 2 g |
| VDS                    | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| VDS, No LAP, if allergic to penicillin then omit ceftriaxone and increase azithromycin dose to 2 g |
| VDS, Patient <35 years old |
| MUS                    | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| MUS, If allergic to penicillin then omit ceftriaxone and increase azithromycin dose to 2 g |
| MUS, Patient <35 years old |
| SSW                    | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| SSW, No indication for surgical assessment |
| GUS                    | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| GUS, Sex within the last 3 months |
| GUS, If no improvement |
| Syphilis               | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Syphilis, Sex within the last 3 months |
| Treatment of more than one STI syndrome |
| MUS + SSW              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| MUS + SSW, Treat according to SSW flowchart |
| MUS + BAL              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| MUS + BAL, Treat according to MUS flowchart |
| MUS + GUS              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| MUS + GUS, Treat according to MUS flowchart |
| VDS + LAP              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| VDS + LAP, Treat according to LAP flowchart and treat for candidiasis, if required |
| VDS + GUS              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| VDS + GUS, Treat for candidiasis, if required |
| LAP + GUS              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| LAP + GUS, Treat for candidiasis, if required |
| SSW + GUS              | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

STI = sexually transmitted infection; stat = immediately as a single dose; IM = intramuscular; MU = million units; LAP = lower abdominal pain; UTI = urinary tract infection; VDS = vaginal discharge syndrome; MUS = male urethritis syndrome; SSW = scrotal swelling; GUS = genital ulcer syndrome; BAL = balanitis/balanoposthitis.
Similarly, the risk of STI diagnosis was higher among patients who were in WHO stages 3 (aHR 1.1; 95% CI 1.0 - 1.3) or 4 (aHR 1.6; 95% CI 1.3 - 1.9) at ART start compared with those in WHO stage 1. In contrast, there was a 20% increase in the risk of STI diagnosis among obese patients compared with those who were underweight at ART initiation (aHR 1.3; 95% CI 1.0 - 1.7). However, >80% of obese patients who experienced an incident STI had a CD4 count <200 cells/µL.

**Discussion**

We sought to determine the incidence of STIs among HIV-positive adult patients in their first 24 months of HIV treatment in Johannesburg. Overall, 7% of our sample had at least one STI episode in the first 2 years on ART, at an incidence rate of 4.8/100 py. This

---

**Table 2. Demographic characteristics of patients on ART in a public hospital in Johannesburg, South Africa, by sex and pregnancy status at ART start (among females)**

|                        | Female, pregnant at ART start (N=280), n (%) | Female, not pregnant at ART start (N=16 150), n (%) | Male (N=10 332), n (%) | Total (N=26 762), n (%) |
|------------------------|---------------------------------------------|---------------------------------------------------|------------------------|------------------------|
| **Age (years) at ART start** |                                             |                                                   |                        |                        |
| ≤30                    | 148 (52.9)                                  | 4 649 (28.8)                                     | 1 550 (15.0)           | 6 347 (23.7)           |
| 31 - 40                | 130 (46.4)                                  | 6 652 (29.3)                                     | 4 844 (46.9)           | 11 629 (43.4)          |
| 41 - 50                | 1 (0.4)                                     | 3 489 (39.4)                                     | 2 790 (27.0)           | 6 280 (23.5)           |
| ≥51                    | 1 (0.4)                                     | 4 409 (27.1)                                     | 1 148 (11.1)           | 2 509 (9.4)            |
| **Employment status at ART start** |                                             |                                                   |                        |                        |
| No                     | 154 (55.6)                                  | 4 374 (43.4)                                     | 4 393 (43.2)           | 12 779 (49.0)          |
| Yes                    | 123 (44.4)                                  | 5 693 (56.6)                                     | 5 766 (56.8)           | 13 325 (51.0)          |
| **Education level at ART start** |                                             |                                                   |                        |                        |
| No education           | 8 (3.5)                                     | 720 (5.5)                                        | 514 (6.1)              | 1 242 (5.7)            |
| Primary education      | 21 (9.3)                                    | 1 866 (14.2)                                     | 1 406 (16.8)           | 3 293 (15.2)           |
| Secondary education    | 197 (87.2)                                  | 10 537 (80.3)                                    | 6 448 (77.1)           | 17 182 (79.1)          |
| **CD4 (cells/µL) at ART start** |                                             |                                                   |                        |                        |
| 0 - 100                | 70 (29.9)                                   | 5 858 (44.1)                                     | 4 571 (52.5)           | 10 499 (47.2)          |
| 101 - 200              | 95 (40.6)                                   | 4 284 (32.2)                                     | 2 518 (28.9)           | 6 897 (31.0)           |
| 201 - 350              | 56 (23.1)                                   | 2 437 (18.3)                                     | 1 319 (15.1)           | 3 810 (17.1)           |
| >350                   | 15 (6.4)                                    | 715 (5.4)                                        | 302 (3.5)              | 1 032 (4.6)            |
| **BMI (kg/m²) at ART start** |                                             |                                                   |                        |                        |
| <18.5                  | 15 (6.7)                                    | 1 898 (15.1)                                     | 1 937 (24.1)           | 3 850 (18.7)           |
| 18.5 - 24.9            | 113 (50.4)                                  | 6 245 (50.8)                                     | 5 075 (63.1)           | 11 433 (55.6)          |
| 25 - 29.9              | 66 (29.5)                                   | 2 652 (21.6)                                     | 844 (10.4)             | 3 562 (17.3)           |
| ≥30                    | 30 (13.4)                                   | 1 506 (12.2)                                     | 183 (2.3)              | 1 719 (8.4)            |
| **WHO stage at ART start** |                                             |                                                   |                        |                        |
| 1                      | 218 (77.9)                                  | 10 921 (67.6)                                    | 6 362 (61.6)           | 17 501 (65.4)          |
| 2                      | 2 (0.7)                                     | 201 (1.2)                                        | 98 (0.9)               | 301 (1.1)              |
| 3                      | 49 (17.5)                                   | 4 049 (25.1)                                     | 3 042 (29.3)           | 7 140 (26.7)           |
| 4                      | 11 (3.9)                                    | 979 (6.1)                                        | 830 (8.0)              | 1 820 (6.8)            |
| **History of alcohol consumption at ART start** |                                             |                                                   |                        |                        |
| No                     | 212 (92.6)                                  | 12 513 (92.5)                                    | 6 409 (75.2)           | 18 869 (85.8)          |
| Yes                    | 9 (3.9)                                     | 993 (7.5)                                        | 2 113 (24.8)           | 3 117 (14.2)           |
| **History of smoking at ART start** |                                             |                                                   |                        |                        |
| No                     | 215 (96.8)                                  | 12 147 (90.0)                                    | 6 332 (72.9)           | 18 691 (83.4)          |
| Yes                    | 9 (3.9)                                     | 737 (5.5)                                        | 2 058 (18.6)           | 2 359 (10.5)           |
| **STI in the first 24 months of ART** |                                             |                                                   |                        |                        |
| No                     | 265 (94.6)                                  | 14 786 (91.6)                                    | 9 805 (94.9)           | 24 856 (92.9)          |
| One or more episodes   | 15 (5.4)                                    | 1 364 (8.4)                                      | 527 (5.1)              | 1 906 (7.1)            |
| **History of TB at ART start** |                                             |                                                   |                        |                        |
| No                     | 23 (8.2)                                    | 959 (5.9)                                        | 803 (7.8)              | 1 785 (6.7)            |
| Yes                    | 257 (91.8)                                  | 15 191 (94.1)                                    | 9 529 (92.2)           | 24 977 (93.3)          |

ART = antiretroviral therapy; BMI = body mass index; WHO = World Health Organization; STI = sexually transmitted infection; TB = tuberculosis.

**Table 3. Proportions of sexually transmitted infections in ART patients in a public hospital in Johannesburg, South Africa**

| Sexually transmitted infection | n (%) |
|-------------------------------|-------|
| Chancroid                     | 2 (0.1) |
| Chlamydia                     | 10 (0.5) |
| Syphilis                      | 15 (0.8) |
| Gonococcal infection          | 11 (0.6) |
| Herpes simplex                | 261 (13.7) |
| Trichomoniasis                | 18 (0.9) |
| Anogenital warts              | 310 (16.3) |
| Unspecified sexually transmitted | 81 (4.2) |
| Syndromic management          | 1 198 (67.1) |

ART = antiretroviral therapy.
Women who were not pregnant at ART initiation had a higher STI incidence (5.7/100 py) than men, which is much lower than the estimated 20/100 py incidence estimates among HIV-negative female trial participants in SA. Similar to previous studies, our results also indicate that younger women had a higher STI risk than men. The higher risk among non-pregnant women may be associated with their higher healthcare-seeking tendencies compared with men.

Predicators of STIs included a low CD4 count, advanced WHO stage and high BMI at ART initiation. While we did not report on health status indicators at the time of the STI episodes, our findings are consistent with other studies showing that immunocompromised individuals are generally more vulnerable to STIs. Patients with weak immune systems (as indicated by a low CD4 count) but in apparent good health (high BMI) seem to be at high risk. However, there could also be a potential diagnostic bias in a population that is already facing diagnostic bias in a population that is already facing it. Also, the sensitivity of this indirect prescription-based STI identification method must be assessed against direct sample testing to establish the margin of error to expect in monitoring the spread of HIV, closer monitoring of STIs and other pathogens.

Nevertheless, STIs in this population primarily indicate high-risk sexual activity. Viral load data were minimal among patients with STI episodes. However, the majority of those with viral load data were suppressed. While HIV treatment reduces infectiousness by controlling viral load, this is only the case among ART-adherent and virally suppressed patients. The risk for onward HIV transmission remains a reality among patients with transient viral suppression, particularly during an STI episode. Patients should therefore be encouraged to use barrier methods and to seek healthcare as soon as STI symptoms manifest.

Study limitations
The data for this analysis were drawn from a single HIV clinic in Johannesburg that may not be representative of other settings in SA. Furthermore, the reliance on diagnosis notes and prescription data does not take into account asymptomatic patients who did not present for care and introduces the potential for care-seeking and diagnostic bias. Also, the data for this analysis were drawn from a single HIV clinic in Johannesburg that may not be representative of other settings in SA. The data for this analysis were drawn from a single HIV clinic in Johannesburg that may not be representative of other settings in SA. The data for this analysis were drawn from a single HIV clinic in Johannesburg that may not be representative of other settings in SA.

Conclusions
STIs are common in HIV-infected patients who are receiving ART. While both ART and the syndromic management of STIs are high-impact interventions for controlling the spread of HIV, closer monitoring of STI occurrences is warranted, particularly among immunologically vulnerable patients.
Table 5. Predictors of STIs among ART patients in a public hospital in Johannesburg, South Africa

| Variable                                      | STI, n (%) | Person-time (100 py) | Failure, n | Incidence rate per 100 py (95% CI) | cHR (95% CI) | aHR (95% CI) |
|-----------------------------------------------|------------|----------------------|------------|-------------------------------------|--------------|--------------|
| **Sex**                                       |            |                      |            |                                     |              |              |
| Male                                          | 527 (5.1)  | 143.75               | 517        | 3.6 (3.3 - 3.9)                     | 1            | 1            |
| Female, pregnant                              | 15 (5.4)   | 4.23                 | 15         | 3.5 (2.1 - 5.8)                     | 0.9 (0.6 - 1.7) | 0.8 (0.4 - 1.5) |
| Female, not pregnant                          | 1 364 (8.4)| 235.68               | 1 341      | 5.7 (5.4 - 6.0)                     | 1.6 (1.4 - 1.8) | 1.6 (1.4 - 1.8) |
| **Age at ART start (years)**                  |            |                      |            |                                     |              |              |
| ≤30                                           | 562 (8.9)  | 88.47                | 550        | 6.2 (5.7 - 6.7)                     | 1            | 1            |
| 31 - 40                                       | 895 (7.7)  | 168.38               | 880        | 5.2 (4.9 - 5.6)                     | 0.8 (0.7 - 0.9) | 0.8 (0.7 - 0.9) |
| 41 - 50                                       | 356 (5.7)  | 91.42                | 352        | 3.9 (3.5 - 4.3)                     | 0.6 (0.5 - 2.0) | 0.6 (0.5 - 0.7) |
| ≥51                                           | 93 (3.7)   | 35.39                | 91         | 2.5 (2.1 - 3.2)                     | 0.4 (0.3 - 0.5) | 0.4 (0.3 - 0.5) |
| **CD4 count (cells/µL) at ART start**         |            |                      |            |                                     |              |              |
| 0 - 100                                       | 927 (8.8)  | 136.94               | 909        | 6.6 (6.2 - 7.1)                     | 1            | 1            |
| 101 - 200                                     | 542 (7.9)  | 103.09               | 531        | 5.1 (4.7 - 5.6)                     | 0.8 (0.7 - 0.9) | 0.8 (0.7 - 0.9) |
| 201 - 350                                     | 180 (4.7)  | 61.00                | 177        | 2.9 (2.5 - 3.3)                     | 0.5 (0.4 - 0.7) | 0.5 (0.4 - 0.6) |
| >350                                          | 42 (4.1)   | 16.01                | 42         | 2.6 (2.1 - 3.2)                     | 0.4 (0.3 - 0.6) | 0.4 (0.3 - 0.6) |
| **Baseline BMI**                              |            |                      |            |                                     |              |              |
| Underweight                                   | 292 (7.6)  | 48.19                | 284        | 5.9 (5.2 - 6.6)                     | 1            | 1            |
| Normal                                        | 955 (8.4)  | 166.41               | 936        | 5.6 (5.3 - 6.0)                     | 1.0 (0.9 - 1.1) | 1.1 (1.0 - 1.3) |
| Overweight                                    | 296 (8.3)  | 55.12                | 293        | 5.3 (4.7 - 6.0)                     | 0.9 (0.8 - 1.1) | 1.2 (1.0 - 1.5) |
| Obese                                         | 151 (8.8)  | 27.29                | 150        | 5.5 (4.7 - 6.5)                     | 1.0 (0.8 - 1.2) | 1.3 (1.0 - 1.7) |
| **WHO staging**                               |            |                      |            |                                     |              |              |
| 1                                             | 1 087 (6.2)| 263.59               | 1 074      | 4.1 (3.8 - 4.3)                     | 1            | 1            |
| 2                                             | 24 (7.9)   | 4.62                 | 24         | 5.2 (3.5 - 7.7)                     | 1.3 (0.9 - 1.9) | 0.9 (0.5 - 1.5) |
| 3                                             | 620 (8.7)  | 94.78                | 609        | 6.4 (5.9 - 6.9)                     | 1.5 (1.4 - 1.7) | 1.1 (1.0 - 1.3) |
| 4                                             | 175 (9.6)  | 20.66                | 166        | 8.0 (6.8 - 9.3)                     | 1.9 (1.6 - 2.2) | 1.6 (1.3 - 1.9) |
| **Employment at ART start**                   |            |                      |            |                                     |              |              |
| No                                            | 965 (7.5)  | 174.11               | 951        | 5.4 (5.1 - 5.8)                     | 1.0 (0.8 - 0.9) | 0.9 (0.8 - 1.0) |
| Yes                                           | 911 (6.8)  | 201.27               | 894        | 4.4 (4.1 - 4.7)                     | 0.8 (0.8 - 0.9) | 0.9 (0.8 - 1.0) |
| **Education at ART start**                    |            |                      |            |                                     |              |              |
| No education                                  | 82 (6.6)   | 17.15                | 80         | 4.6 (3.7 - 5.8)                     | 1.0 (0.8 - 1.3) | 1.0 (0.8 - 1.3) |
| Primary school                                | 222 (6.7)  | 47.60                | 218        | 4.5 (4.0 - 5.2)                     | 1.0 (0.8 - 1.3) | 1.0 (0.8 - 1.3) |
| Secondary school                              | 1 155 (6.7)| 259.24               | 1 137      | 4.3 (4.2 - 5.5)                     | 1.0 (0.8 - 1.2) | 1.0 (0.8 - 1.2) |
| **History of alcohol consumption at ART start**|            |                      |            |                                     |              |              |
| No                                            | 1 404 (7.5)| 274.81               | 1 384      | 5.1 (4.8 - 5.3)                     | 1            | 1            |
| Yes                                           | 200 (6.4)  | 40.81                | 197        | 4.8 (4.2 - 5.6)                     | 0.9 (0.8 - 1.1) | 0.9 (0.8 - 1.1) |
| **History of smoking at ART start**           |            |                      |            |                                     |              |              |
| No                                            | 1 436 (7.5)| 279.50               | 1 416      | 5.1 (4.8 - 5.4)                     | 1            | 1            |
| Yes                                           | 169 (6.2)  | 36.62                | 166        | 4.5 (3.9 - 5.3)                     | 0.9 (0.7 - 1.0) | 0.9 (0.7 - 1.0) |

STI = sexually transmitted infection; ART = antiretroviral therapy; py = person-years; CI = confidence interval; cHR = crude hazard ratio; aHR = adjusted hazard ratio; BMI = body mass index; WHO = World Health Organization.
Declaration. None.

Acknowledgements. The authors gratefully acknowledge the directors and staff of the Themba Lethu HIV clinic as well as Right to Care, the non-governmental organisation supporting the study site through a partnership of the SA national and Gauteng provincial departments of health with the United States Agency for International Development (USAID). Most of all we thank the patients attending the Themba Lethu clinic for their continued trust in the treatment provided.

Author contributions. PM, CN, SK, MM and MPF contributed equally to the work. DO, PM, CN and MPF conceptualised the analysis. PM and SK analysed the data and drafted the manuscript. KS and MM assisted in the analysis of data and contributed to the interpretation of the results as well as the manuscript preparation.

Funding. This study has been made possible by the generous support of the American people and the President’s Emergency Plan for AIDS Relief (PEPFAR) through USAID under the terms of Cooperative Agreements AID-674-A-12-00029 and 72067419CA00004 to the Health Economics and Epidemiology Research Office, Cooperative Agreement 674-A-00-09-00018-00 to Boston University and Cooperative Agreement 674-A-12-00020 to Right to Care. The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID or the US government.

The funders had no role in the study design, collection, analysis and interpretation of the data, manuscript preparation, or the decision to publish.

Conflicts of interest. None.

1. Maynard P, Malley D. Approaches to the control of sexually transmitted infections in developing countries: Old problems and modern challenges. Sex Transm Infect 2004;80(3):174-182. https://doi.org/10.1136/sti.2002.004901
2. Kalaatime RS, Nai R, Rowley J, et al. Adult gonorrhoea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: Estimates using the Spectrum-STI model, 1990 - 2017. PLoS ONE 2018;13(10):e0205663. https://doi.org/10.1371/journal.pone.0205663
3. National Department of Health, South Africa. The 2015 National Antenatal Sentinel HIV & Syphilis Survey, South Africa. Pretoria: NDoH, 2017. http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-18/2015-04-30-08-21-56/download?2584-2015-national-antenatal-hiv-prevalence-survey-final-25oct17 (accessed 18 November 2020).
4. Bauer T, Takaro T, Mulembo K, Yoneta N, Nyando PS. Prevalence and risk factors for self-reported sexually transmitted infections among adults in the Daspodot informal settlement, Johannesburg, South Africa. J AIDS Clin Res 2016;7:39. https://doi.org/10.4172/2155-613X.1000589
5. Johnson LE, Dorrington RE, Modla H. Progress towards the 2020 target for HIV diagnosis and antiretroviral treatment in South Africa. South Afr J HIV Med 2017;18(1):1-8. https://doi.org/10.4102/ sajhm.v18i1.991
6. Newmark L, Rockey J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global PLoS ONE 2015;10(12):e0143504. https://doi.org/10.1371/journal.pone.0143504
7. Haggerty CL, Gotlib SL, Taylor BD, Low N, Xu F, New BB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010;201(Suppl 2):S184-S185. https://doi.org/10.1086/652995
8. Johnson LE, Chiu C, Myers L, et al. Prospects for HIV control in South Africa: A model-based analysis. Glob Health Action 2016;9:30134. https://doi.org/10.3402/gha.v9.30134
9. Johnson LE, Dorrington RE, Bradshaw D, Coetzee D. The role of sexually transmitted infections in the evolution of the South African HIV epidemic. Trop Med Int Health 2012;17(2):161-168. https://doi.org/10.1111/j.1365-3156.2011.02996.x
10. Sexton J, Garnett G, Rottingen JA. Meta-analysis and meta-regression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005;32(6):351-357. https://doi.org/10.1097/01.olq.0000154504.54686.d1
11. Boux WR. Syndromic management of sexually transmitted diseases: Is it rational or scientific? Trop Med Int Health 2002;7(2):114-119. https://doi.org/10.1046/j.1365-3156.1999.00860.x
12. National Institute for Communicable Diseases. GERM5 South Africa Annual Report 2017. Johannesburg: NICD, 2017. https://www.siteresources.stat.gov.za/wp-content/uploads/2018/08/GERM5-SA_AR-2017-final.pdf (accessed 18 November 2020).
13. Kaia A, Dietrich JJ, Laber F, et al. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: Implications for HIV prevention efforts. BMC Infect Dis 2018;18(1):499. https://doi.org/10.1186/ s12879-018-3380-4
14. World Health Organisation. Report on global sexually transmitted infection surveillance 2018. Geneva: WHO, 2018. https://www.who.int/reproductivehealth/publications/si-surveillance-2018-en/ (accessed 18 November 2020).
15. National Department of Health, South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: NDoH, 2015. https://siteresources.stat.gov.za/OFRS%20Guidelines%202015.pdf (accessed 11 December 2020).
16. National Department of Health, South Africa. Sexually transmitted infections management guidelines, 2015. Pretoria: NDoH, 2015. https://health-sa org.co.za/2015/08/25/guidelines-sexually-transmitted-infection-management-guidelines-2015/ (accessed 18 November 2020).
17. Naide S, Wand H, Ababi NS, Rambje G. High prevalence and incidence of sexually transmitted infections among women living in KwaZulu-Natal, South Africa. AIDS Res Ther 2014;11:31. https://doi.org/10.1186%2F1742-6405-11-31
18. Bosu WK. Syndromic management of sexually transmitted diseases: Is it rational or scientific? Trop Med Int Health 2002;7(2):114-119. https://doi.org/10.1046/j.1365-3156.1999.00860.x
19. National Department of Health, South Africa. The 2015 national antenatal sentinel sentinel HIV & syphilis survey, South Africa. Pretoria: NDoH, 2015. http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-18/2015-04-30-08-21-56/download?2584-2015-national-antenatal-hiv-prevalence-survey-final-25oct17 (accessed 18 November 2020).
20. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV in South Africa: Implications for HIV prevention efforts. BMC Infect Dis 2018;18(1):499. https://doi.org/10.1186/ s12879-018-3380-4
21. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010;50(0 3):S85-S95. https://doi.org/10.1086%2F651478
22. Sexton J, Garnett G, Rottingen JA. Meta-analysis and meta-regression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005;32(6):351-357. https://doi.org/10.1097/01.olq.0000154504.54686.d1
23. Boulle A, Pillay D, Deeks SG, et al. The risk of complications in patients with HIV and tuberculosis. N Engl J Med 2007;356(12):1191-1200. https://doi.org/10.1056/NEJMoa065719
24. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV in South Africa: Implications for HIV prevention efforts. BMC Infect Dis 2018;18(1):499. https://doi.org/10.1186/ s12879-018-3380-4
25. National Department of Health, South Africa. The 2015 national antenatal sentinel sentinel HIV & syphilis survey, South Africa. Pretoria: NDoH, 2015. http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-18/2015-04-30-08-21-56/download?2584-2015-national-antenatal-hiv-prevalence-survey-final-25oct17 (accessed 18 November 2020).

Accepted 5 June 2020.